NDAINTRAVENOUSSOLUTION
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE (pantoprazole sodium in 0.9% sodium chloride) by Baxter is (h, k)-atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for pathological hypersecretory conditions including zollinger-ellison (ze) syndrome in adults. First approved in 2024.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pantoprazole sodium 40 mg in 0.9% sodium chloride is an intravenous proton pump inhibitor that binds irreversibly to the (H, K)-ATPase enzyme on gastric parietal cells to suppress gastric acid secretion. It is indicated for pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults, with antisecretory effects persisting beyond 24 hours. The IV formulation enables rapid onset of action in acute care settings where oral administration is not feasible.
Growth
Early-stage IV product with moderate competitive pressure; expect investment in field sales, specialty pharmacy partnerships, and hospital formulary teams as adoption ramps post-approval.
Mechanism of Action
(H, K)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H, K)-ATPase results in a duration of antisecretory effect that persists longer…
Career Relevance
Early-stage IV product with targeted niche in acute care and specialty gastroenterology; career opportunities focus on hospital formulary penetration, specialty pharmacy partnerships, and establishing clinical evidence in practice. Baxter sponsorship and moderate competitive pressure suggest mid-sized commercial infrastructure with growth potential as adoption expands.
Worked on PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.